ArteraAI alternatives and competitors
The closest alternatives to ArteraAI are Valar Labs, DoMore Diagnostics, Veracyte and PreciseDx.
ArteraAI is the Los Altos, California company at artera.ai that builds multimodal AI cancer tests. It is unrelated to Artera of Santa Barbara (artera.io), which makes patient communication agents.
10 alternatives to ArteraAI
What each product does, with its price as the vendor publishes it.
-
V
Valar Labs is a precision oncology company, founded in 2021, whose tests predict treatment response and prognosis from routine H and E slides using its Computational Histology AI platform, trained on more than 500,000 pathologist annotations.
-
D
Histotype Px Colorectal predicts recurrence and survival in stage II and III colorectal cancer from standard H and E stained slides, placing patients in low, intermediate or high risk groups to inform whether adjuvant chemotherapy should follow surgery.
Price: No published price
-
V
Veracyte sells genomic tests that pair a laboratory expression assay with a learned classifier, used by urologists, oncologists and endocrinologists to decide how intensively to treat a cancer or whether a thyroid nodule needs surgery.
Price: No published price
-
P
PreciseDx sells PreciseBreast, a test that predicts whether early breast cancer will come back, using AI to read the cell patterns on a routine stained slide.
Price: No published price
-
S
Stratipath Breast assigns early stage invasive breast cancers to low or high risk groups from routine H&E slides, as a faster, cheaper alternative to gene expression tests for pathology laboratories and breast cancer teams in Europe.
Price: No published price
-
D
Deep Bio builds deep learning algorithms for cancer pathology, led by prostate.
Price: No pricing published; sold through third party platforms, unit of charge unstated
-
L
Lumea's argument is that digital pathology fails upstream of the software, at the specimen, so its products start at the biopsy.
-
P
Paige sells AI applications that help pathologists find and classify cancer on digitized slides, for prostate, breast, gastrointestinal and pan cancer pathology, along with a pathologist co-pilot called Alba, the FullFocus viewer and a family of foundation models (Virchow, Virchow2…
-
G
Multi cancer early detection company (NASDAQ: GRAL). The Galleri test uses targeted methylation sequencing of cell free DNA from a blood draw, with machine learning classifiers that detect a cancer signal and predict its origin, across more than 50 cancer types.
Price: $949 per test (list price)
-
G
Guardant Health is a publicly traded precision oncology company (Nasdaq: GH), founded in 2012 and based in Palo Alto, California, that runs blood and tissue cancer tests in its own laboratories.
More ArteraAI comparisons
Side by side comparisons of ArteraAI with products not listed above.
ArteraAI alternatives, answered
What are the best alternatives to ArteraAI?
The closest alternatives to ArteraAI are Valar Labs, DoMore Diagnostics, Veracyte, PreciseDx and Stratipath. Valar Labs is a precision oncology company, founded in 2021, whose tests predict treatment response and prognosis from routine H and E slides using its Computational Histology AI platform, trained on more than 500,000 pathologist annotations. Veracyte sells genomic tests that pair a laboratory expression assay with a learned classifier, used by urologists, oncologists and endocrinologists to decide how intensively to treat a cancer or whether a thyroid nodule needs surgery. PreciseDx sells PreciseBreast, a test that predicts whether early breast cancer will come back, using AI to read the cell patterns on a routine stained slide.
Who are ArteraAI's competitors?
ArteraAI's competitors in the Digital Pathology AI category include Valar Labs, DoMore Diagnostics, PreciseDx, Stratipath, Deep Bio and Lumea.